By Toni Clarke (Reuters) - Amarin Corporation Plc's triglyceride-lowering drug Vascepa should not be approved for use in a broader patient population until results from an additional study have been analyzed, an advisory panel to the U.S. Food and Drug Administration recommended on Wednesday. The panel voted 9-2 against approval of the drug for patients who also take a cholesterol-lowering statin such as Pfizer Inc's Lipitor and are at high risk of coronary heart disease. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/u-fda-panel-votes-against-expanded-amarin-drug-191229743--finance.html
via Health News Headlines - Yahoo! News http://news.yahoo.com/u-fda-panel-votes-against-expanded-amarin-drug-191229743--finance.html
No comments:
Post a Comment